Despite new challenges in shingles, Merck's vaccine business kept churning in 2017, generating sales of $6.5 billion—an increase of 4.8%.Original Article
Gardasil grows, Zostavax struggles as Merck posts $6.5B in 2017 vaccine sales
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.